Literature DB >> 27162011

1-(5-Carboxyindazol-1-yl)propan-2-ones as dual inhibitors of cytosolic phospholipase A2α and fatty acid amide hydrolase: bioisosteric replacement of the carboxylic acid moiety.

Jan Althaus1, Theresa Hake1, Walburga Hanekamp1, Matthias Lehr1.   

Abstract

Indazole-5-carboxylic acids with 3-aryloxy-2-oxopropyl residues in position 1 were previously reported to be potent dual inhibitors of cytosolic phospholipase A2α (cPLA2α) and fatty acid amide hydrolase (FAAH). In continuation of our structure-activity studies on cPLA2α and FAAH inhibitors, a number of derivatives of these substances characterized by bioisosteric replacement of the carboxylic acid functionality by inverse amides, sulfonylamides, carbamates and ureas were prepared. The biological evaluation of the obtained compounds showed that the carboxylic acid functionality of the lead compounds is of special importance for a pronounced inhibition of cPLA2α and FAAH.

Entities:  

Keywords:  Bioisosteric replacement; cytosolic phospholipase A2α; fatty acid amide hydrolase; indazol-1-ylpropan-2-ones; inhibitor

Mesh:

Substances:

Year:  2016        PMID: 27162011     DOI: 10.1080/14756366.2016.1178246

Source DB:  PubMed          Journal:  J Enzyme Inhib Med Chem        ISSN: 1475-6366            Impact factor:   5.051


  3 in total

1.  Synthesis and stability of strongly acidic benzamide derivatives.

Authors:  Frederik Diness; Niels J Bjerrum; Mikael Begtrup
Journal:  Beilstein J Org Chem       Date:  2018-02-27       Impact factor: 2.883

Review 2.  Small-molecule inhibitors as potential therapeutics and as tools to understand the role of phospholipases A2.

Authors:  Aikaterini Nikolaou; Maroula G Kokotou; Sofia Vasilakaki; George Kokotos
Journal:  Biochim Biophys Acta Mol Cell Biol Lipids       Date:  2018-08-23       Impact factor: 4.698

Review 3.  Terminal Phenoxy Group as a Privileged Moiety of the Drug Scaffold-A Short Review of Most Recent Studies 2013-2022.

Authors:  Paweł Kozyra; Monika Pitucha
Journal:  Int J Mol Sci       Date:  2022-08-09       Impact factor: 6.208

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.